Merck & Co.’s cancer wunderkind Keytruda continues to turn in supercharged sales, $2.27 billion in Q1, which bodes well for the future of biologics manufacturing jobs at the company. But woe to those who work at other facilities, because the company has undertaken a manufacturing restructuring that could cost up to $1.2 billion when the dust settles.
